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Biomarkers are useful tools for diagnosis and risk
assessment of acute kidney injury and acute heart
failure, particularly in ICU patients. Most biomarkers
are produced or cleared by the kidney, so the
presence of chronic kidney disease may affect their
clinical reliability, particularly if the putative diagnosis
of acute kidney injury or acute heart failure is based
on a single measurement/single threshold approach.
Better alternatives, such as establishing different
diagnostic cutoff values per different chronic kidney
disease strata or evaluating the diagnostic
performance of a delta value (change from baseline
levels) instead of a single threshold, should be
carefully considered in critically ill patients with renal
impairment and other co-morbidities.
Chronic kidney disease (CKD) is highly prevalent in the
ICU population and conveys a higher risk of
developing both acute kidney injury (AKI) and acute
heart failure (AHF). Early serum and urine biomarkers
of AKI and AHF may improve diagnosis and risk
stratification. Most biomarkers are affected by renal
function impairment, however, so the presence of
CKD may hamper their predictive capacity.no differences were reported in patients with baselineDonadio investigated whether the presence of underlying
CKD may affect the diagnostic performance of two
of the most studied biomarkers of cardio-renal damage,
namely neutrophil gelatinase-associated lipocalin (NGAL)
and brain natriuretic peptide (BNP) [1]. In this study,
plasma NGAL increased in a parallel fashion with the
reduction in glomerular filtration rate (GFR), generating
a very high number of false positive diagnoses of AKI* Correspondence: davide.bolignano@gmail.com
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2014in stable CKD patients. Conversely, urinary NGAL and
plasma BNP were less affected by reduced GFR.
NGAL is a kidney stress protein, the levels of which
increase in plasma and urine of patients developing AKI,
2 to 8 hours after renal injuries of various nature [2].
Although the predictive performance of NGAL was
remarkable in pediatric populations, conflicting results
emerged in the adult setting. In particular, studies report-
ing an excellent discriminant ability mostly excluded
patients with preoperative CKD, whereas a more modest
performance was reported in those also including pa-
tients with impaired renal function [3]. In CKD patients,
NGAL levels are strictly, independently and inversely
correlated to residual GFR, probably as the consequence
of an active production by the damaged but still vital
tubule that goes along with the functional decrease of
renal parenchyma [4].
The effect of baseline renal function on the diagnostic
performance of urinary NGAL was also evaluated re-
cently by McIlroy and colleagues in a prospective obser-
vational study in 426 adults undergoing major cardiac
surgery [5]. In patients with baseline GFR >60 ml/minute
who developed AKI, urinary NGAL was higher at all
postoperative time points compared with those pa-
tients who did not have this complication. Conversely,
GFR <60 ml/minute. Postoperative NGAL best identified
AKI in patients with baseline GFR 90 to 120 ml/minute,
therefore suggesting that the optimal discriminatory per-
formance is achieved in patients with normal preopera-
tive renal function.
As is well known, BNP is mostly useful for screening
and prognosis of acute and chronic heart dysfunction.
Although less than 5% of BNP is cleared by the renal route,
accruing evidence indicates that the circulating levels of
this biomarker are elevated in CKD patients despite an
apparently conserved ventricular function [6,7]. In addition,
elevated BNP levels predict accelerated progression of
CKD in patients with mild to moderate renal impairment,Med Central Ltd. The licensee has exclusive rights to distribute this article, in
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levels could therefore be helpful in the management of com-
bined heart and kidney disease, these observations might
raise concerns regarding the specificity of BNP as biomarker
of AHF in the scenario of CKD. Challenging the issue of
baseline renal function is thus crucial for validating the po-
tential usefulness of biomarkers in clinical practice. Even the
measurement of widely implemented biomarkers, such as
troponins or tumor markers [9,10], often leads to misleading
clinical interpretations in CKD (especially dialysis) patients.
For biomarkers of AKI and AHF, we believe that, as a
general rule, one size (that is, one threshold) cannot fit
all. In other words, it is virtually impossible to consider
univocal cutoff values able to stratify the risk of AKI or
AHF in a miscellaneous population of critically ill pa-
tients as a whole. Considering different diagnostic
thresholds for different CKD strata might help to im-
prove the overall performance of NGAL and BNP but,
predictably, this would not reduce the ground noise
caused by other confounders. For instance, apart from
renal damage, NGAL levels are known to be affected
also by proteinuria, systemic inflammation, oxidative
stress, iron balance, diabetes and existing cardiovascular
disease [11], while BNP can be influenced by chronic
heart failure, obesity, inflammation and even age, gender
and heart rate [12]. This variation makes it virtually im-
possible to find baseline values of these biomarkers fall-
ing within the normal range, even in ICU patients with
normal renal function or early stage CKD. In view
of this, a single-time, threshold-based measurement of
NGAL or BNP as an exclusive tool for predicting AKI or
AHF should probably be called into question. Even if a
cost–benefit analysis must always be taken into account,
it would be good to verify whether the predictive cap-
acity of a delta value (variation in biomarkers levels be-
tween end of procedure and baseline; for example, time
of admission in the ICU) would be superior to that of a
single biomarker measurement.
In conclusion, the presence of CKD may actually im-
pact upon the diagnostic performance and reliability of
biomarkers of acute damage of kidney and heart. This
holds true for biomarkers already used in daily clinical
practice as well as for those emerging biomarkers whose
promising, preliminary findings in homogeneous study
cohorts still await an external validation. Since CKD is
exceedingly prevalent in ICU patients, taking systematic-
ally into account the effect of residual renal function
might enhance the diagnostic performance of bio-
markers for the risk stratification of cardio-renal compli-
cations in critically ill patients.
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